| 11.13 0.03 (0.27%) | 07-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.24 | 1-year : | 15.47 |
| Resists | First : | 11.34 | Second : | 13.24 |
| Pivot price | 11.05  |
|||
| Supports | First : | 11.06 | Second : | 10.89 |
| MAs | MA(5) : | 11.07  |
MA(20) : | 11.1 |
| MA(100) : | 6.7 |
MA(250) : | 6.28 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 53.4 |
D(3) : | 44.1 |
| RSI | RSI(14): 76.2 | |||
| 52-week | High : | 11.4 | Low : | 2.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VERV ] has closed below upper band by 23.6%. Bollinger Bands are 90% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.14 - 11.2 | 11.2 - 11.23 |
| Low: | 10.99 - 11.07 | 11.07 - 11.12 |
| Close: | 11.02 - 11.14 | 11.14 - 11.21 |
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Thu, 24 Jul 2025
Lilly and Verve announce expiration of Verve tender offer - PR Newswire
Thu, 24 Jul 2025
Lilly completes tender offer for Verve Therapeutics shares - Investing.com
Wed, 18 Jun 2025
Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha
Tue, 17 Jun 2025
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - Yahoo Finance
Tue, 17 Jun 2025
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PR Newswire
Tue, 17 Jun 2025
Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 94.6 (%) |
| Shares Short | 3,630 (K) |
| Shares Short P.Month | 18,000 (K) |
| EPS | -2.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.32 |
| Profit Margin | 0 % |
| Operating Margin | -111.1 % |
| Return on Assets (ttm) | -19.4 % |
| Return on Equity (ttm) | -34.3 % |
| Qtrly Rev. Growth | 479 % |
| Gross Profit (p.s.) | -1.69 |
| Sales Per Share | 0.66 |
| EBITDA (p.s.) | -2.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -142 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -5.28 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 16.67 |
| Price to Cash Flow | -6.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|